PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'State Key Laboratory of Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong, China.\', \'Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China.\', \'Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.\', \'Medical Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.\', \'Key Laboratory of Chinese Internal Medicine of Ministry of Education, Beijing University of Chinese Medicine, Beijing 100070, China. Corresponding author: Zhong Nanshan, Email: nanshan@vip.163.com; Shang Hongcai, Email: shanghongcai@126.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3760/cma.j.cn121430-20210514-00714
?:doi
?:hasPublicationType
?:journal
  • Zhonghua wei zhong bing ji jiu yi xue
is ?:pmid of
?:pmid
?:pmid
  • 34412743
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.15
?:rankingScore_hIndex
  • 5
is ?:relation_isRelatedTo_publication of
?:title
  • [A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019].
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all